These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 39088033

  • 1. Improvements in daytime sleepiness and disrupted nighttime sleep with once-nightly sodium oxybate in people with narcolepsy type 1 and type 2: a plain language summary.
    Dauvilliers Y, Roth T, Bogan R, Thorpy MJ, Morse AM, Ascencion F, Gudeman J.
    J Comp Eff Res; 2024 Sep; 13(9):e240031. PubMed ID: 39088033
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Efficacy of once-nightly sodium oxybate (FT218) in narcolepsy type 1 and type 2: post hoc analysis from the Phase 3 REST-ON Trial.
    Dauvilliers Y, Roth T, Bogan R, Thorpy MJ, Morse AM, Roy A, Dubow J, Gudeman J.
    Sleep; 2023 Nov 08; 46(11):. PubMed ID: 37246913
    [Abstract] [Full Text] [Related]

  • 4. Implications of Oxybate Dosing Regimen for Sleep, Sleep Architecture, and Disrupted Nighttime Sleep in Patients with Narcolepsy: A Commentary.
    Rosenberg R, Braceras R, Macfadden W, Candler S, Black J, Ruoff C.
    Neurol Ther; 2023 Dec 08; 12(6):1805-1820. PubMed ID: 37755650
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Development of a lower-sodium oxybate formulation for the treatment of patients with narcolepsy and idiopathic hypersomnia.
    Junnarkar G, Allphin C, Profant J, Steininger TL, Chen C, Zomorodi K, Skowronski R, Black J.
    Expert Opin Drug Discov; 2022 Feb 08; 17(2):109-119. PubMed ID: 34818123
    [Abstract] [Full Text] [Related]

  • 8. Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON Trial.
    Roth T, Dauvilliers Y, Thorpy MJ, Kushida C, Corser BC, Bogan R, Rosenberg R, Dubow J, Seiden D.
    CNS Drugs; 2022 Apr 08; 36(4):377-387. PubMed ID: 35380374
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Long-Term Treatment of Narcolepsy and Idiopathic Hypersomnia with Low-Sodium Oxybate.
    Schneider LD, Morse AM, Strunc MJ, Lee-Iannotti JK, Bogan RK.
    Nat Sci Sleep; 2023 Apr 08; 15():663-675. PubMed ID: 37621721
    [Abstract] [Full Text] [Related]

  • 11. Effectiveness and optimization of low-sodium oxybate in participants with narcolepsy switching from a high-sodium oxybate: data from the Substitution of Equal Grams of Uninterrupted Xyrem to Xywav study.
    Macfadden W, Leary EB, Fuller DS, Kirby MT, Roy A.
    J Clin Sleep Med; 2024 Sep 01; 20(9):1467-1477. PubMed ID: 38652499
    [Abstract] [Full Text] [Related]

  • 12. Time to response with sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy.
    Bogan RK, Roth T, Schwartz J, Miloslavsky M.
    J Clin Sleep Med; 2015 Apr 15; 11(4):427-32. PubMed ID: 25580605
    [Abstract] [Full Text] [Related]

  • 13. Impact of sodium oxybate, modafinil, and combination treatment on excessive daytime sleepiness in patients who have narcolepsy with or without cataplexy.
    Black J, Swick T, Bogan R, Lai C, Carter LP.
    Sleep Med; 2016 Aug 15; 24():57-62. PubMed ID: 27810187
    [Abstract] [Full Text] [Related]

  • 14. Long-Term Safety and Tolerability During a Clinical Trial and Open-Label Extension of Low-Sodium Oxybate in Participants with Narcolepsy with Cataplexy.
    Bogan RK, Foldvary-Schaefer N, Skowronski R, Chen A, Thorpy MJ.
    CNS Drugs; 2023 Apr 15; 37(4):323-335. PubMed ID: 36947322
    [Abstract] [Full Text] [Related]

  • 15. Clinician Preferences for Oxybate Treatment for Narcolepsy: Survey and Discrete Choice Experiment.
    Morse AM, Krahn L, Flygare J, Kushida C, Thorpy MJ, Athavale A, Gudeman J.
    Adv Ther; 2023 Jul 15; 40(7):3199-3216. PubMed ID: 37243863
    [Abstract] [Full Text] [Related]

  • 16. Cataplexy response with extended-release once-nightly sodium oxybate: Post hoc responder analyses from the phase 3 REST-ON clinical trial.
    Thorpy MJ, Kushida CA, Bogan R, Ajayi AO, Corser BC, Gudeman J.
    Sleep Med X; 2024 Dec 15; 7():100109. PubMed ID: 38601325
    [Abstract] [Full Text] [Related]

  • 17. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy.
    Xyrem International Study Group.
    J Clin Sleep Med; 2005 Oct 15; 1(4):391-7. PubMed ID: 17564408
    [Abstract] [Full Text] [Related]

  • 18. Calcium, magnesium, potassium, and sodium oxybates oral solution for cataplexy or excessive daytime sleepiness associated with narcolepsy.
    Abad VC.
    Expert Opin Pharmacother; 2023 Jun 15; 24(8):875-885. PubMed ID: 37060579
    [Abstract] [Full Text] [Related]

  • 19. Sodium oxybate for narcolepsy with cataplexy: systematic review and meta-analysis.
    Alshaikh MK, Tricco AC, Tashkandi M, Mamdani M, Straus SE, BaHammam AS.
    J Clin Sleep Med; 2012 Aug 15; 8(4):451-8. PubMed ID: 22893778
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of once-nightly sodium oxybate (FT218) on daytime symptoms in individuals with narcolepsy with or without concomitant alerting agent use: A post hoc analysis from the phase 3 REST-ON trial.
    Dauvilliers Y, Roth T, Bogan R, Thorpy MJ, Morse AM, Roy A, Gudeman J.
    Sleep Med; 2024 Dec 15; 124():209-216. PubMed ID: 39321628
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.